Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
J Pharm Biomed Anal ; 212: 114598, 2022 Apr 01.
Artigo em Inglês | MEDLINE | ID: mdl-35152005

RESUMO

Pharmacological treatment of Parkinson's disease consists of a combined chemotherapy that mostly relies on levodopa (L-DOPA) administration together with inhibitors of dopa-decarboxylase (DDC), monoamine oxidase (MAO) and catechol-methyltransferase (COMT). Identification of inhibitors specifically targeting these enzymes is still a significative part of the development of new alternative antiparkinsonian drugs. Most of the available methods use measurement of enzymatic reactions through radioactive labeling, antibody-recognized products or coupled enzymatic assays. Mass spectrometry (MS) represents an interesting alternative approach as it allows direct and specific detection and quantification of enzymatic reactions. We describe the development of a simple, reliable, label-free assay based on high-resolution mass spectrometry (HRMS) for the detection and relative quantification of three different enzymatic reactions using non-isolated enzymes. The assay was applied both to reference drugs and plant crude extracts. This method can be used to detect hits in extracts libraries as well as determine relative IC50 of inhibitors.


Assuntos
Catecol O-Metiltransferase , Monoaminoxidase , Antiparkinsonianos , Inibidores de Catecol O-Metiltransferase/farmacologia , Catecóis/química , Dopa Descarboxilase , Ensaios Enzimáticos , Levodopa/uso terapêutico , Espectrometria de Massas , Inibidores da Monoaminoxidase/farmacologia
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa